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Abstract
Objective: Although absolute values for C-reactive protein (CRP) and procalcitonin (PCT) are well known to predict sepsis in
the critically ill, it remains unclear how changes in CRP and PCT compare in predicting evolution of: infectious disease,
invasiveness and severity (e.g. development of septic shock, organ failure and non-survival) in response to treatment. The
current study attempts to clarify these aspects.
Methods: In 72 critically ill patients with new onset fever, CRP and PCT were measured on Day 0, 1, 2 and 7 after inclusion,
and clinical courses were documented over a week with follow up to Day 28. Infection was microbiologically defined, while
septic shock was defined as infection plus shock. The sequential organ failure assessment (SOFA) score was assessed.
Results: From peak at Day 0–2 to Day 7, CRP decreased when (bloodstream) infection and septic shock (Day 0–2) resolved
and increased when complications such as a new (bloodstream) infection or septic shock (Day 3–7) supervened. PCT
decreased when septic shock resolved and increased when a new bloodstream infection or septic shock supervened.
Increased or unchanged SOFA scores were best predicted by PCT increases and Day 7 PCT, in turn, was predictive for 28-day
outcome.
Conclusion: The data, obtained during ICU-acquired fever and infections, suggest that CRP may be favoured over PCT
courses in judging response to antibiotic treatment. PCT, however, may better indicate the risk of complications, such as
bloodstream infection, septic shock, organ failure and mortality, and therefore might help deciding on safe discontinuation
of antibiotics. The analysis may thus help interpreting current literature and design future studies on guiding antibiotic
therapy in the ICU.
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Introduction
In critically ill patients, new onset fever often prompts clinicians
to search for nosocomial microbial infection and to start empiric
antibiotics in attempts to diminish morbidity and mortality [1–3].
Plasma levels of C-reactive protein (CRP) or procalcitonin (PCT)
are often used to increase the a priori probability of microbial
infection and sepsis in the intensive care unit (ICU) [2–12]. In a
previous study on absolute levels within the first days after new
fever onset in critically ill patients, we found that CRP may
particularly help in predicting local microbial infection and PCT
in predicting bloodstream infection (BSI) and a downhill clinical
course [3]. The clinical relevance of changes in the markers is less
clear, however. Changes in CRP and PCT over 2–7 days have
been described in non-critically ill patient populations [13–20], in
relatively small studies, about 50 patients or less
[4,9,13,15,16,19,21–25], in specific conditions [2,8,10,13,15–
17,19,20,22,24,26–29] or in heterogeneous conditions in the
ICU [4–7,9,11,21,23,30–32], to judge the course of infection and
its sequelae. CRP decreases of more than about 25% per day
within the first week of treatment of (bloodstream) infections or
sepsis have been suggested to help predict a beneficial response
and disease course, while slower decreases or increases have been
associated with persistent infection, organ failure or mortality, also
in the ICU [7,8,11,17–19,21-,23,26–29,32]. A relatively rapid fall
of PCT may be associated with a beneficial outcome of
pneumonia, meningitis, burn-associated or other infections,
whereas a rise may be associated with organ failure and mortality
and thus might have predictive value (5,6,8–10,15,16,20,24,
26,27,30,31]. A fall in PCT below 0.5 ng/mL, a threshold
suggested in studies on non-critically ill patients, has been used to
safely and effectively shorten the duration of administration of
antibiotics for infections in the ICU [33]. CRP and PCT changes
have been compared in their relative ability to detect the evolution
of infection or sepsis, within [4–6,10,24–27,30,31] or outside the
ICU [8,14,15,18,19]. CRP may display slower kinetics than PCT
and in some, but not all studies, decreases or increases of the latter
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may better predict a beneficial or downhill course with resolving or
aggravating organ failure, respectively [2,4,6,8,10,14–16,19,24–
27,30,31,34]. Nevertheless, the relative value of marker changes in
predicting response to antibiotic treatment of ICU-acquired
infections is only rarely addressed [10,15,24,26,27,31]. Hence,
general conclusions on the relative superiority of the markers for
specific endpoints in the critically ill are hard to draw from the
literature and the controversy is ongoing.
In order to further help clinical decision making on the basis of
changes in CRP and PCT in the ICU, we hypothesized for the
current study that, in general critically ill patients with new onset
fever, the 1-week course of CRP and PCT levels can be used to
distinguish resolving microbial infection with a beneficial outcome
from non-resolving or developing infection with a detrimental
outcome associated with BSI, septic shock, organ failure and
death. We also hypothesized that CRP and PCT differ in this
respect, so that CRP primarily predicts the course of local infection
and PCT that of systemic infection and its adverse sequelae. This
would also help to define values at which antibiotic treatment can
be decided as appropriate or to allow safe discontinuation in the
ICU.
Materials and Methods
This is a prospective observational study on causes and
consequences of ICU-acquired fever, approved by the medical
ethical committee of the VU University Medical Center,
Amsterdam, conducted between 2003 and 2007. All patients or
closest relatives gave their written informed consent, leading to
inclusion of 101 consecutive patients with new onset fever,
admitted to a mixed medical/surgical ICU, and the complete
protocol has been described elsewhere [3]. The current analysis is
on the 72 patients having completed a follow up of at least 7 days
in the ICU (Consort diagram Figure S1). To briefly reiterate, a
body temperature .38.3uC measured rectally was the main
inclusion criterion, while admitted to the ICU for at least 24 hours
without fever (body temperature ,37.5uC). Exclusion criteria
were: age under 18 years, pregnancy and life expectancy of ,24
hours. Enrolment had to be completed within 12 hours of meeting
inclusion criteria and was marked Day 0 (D0). Demographic data
were collected. Disease severity was expressed through the
simplified acute physiology scores (SAPS) II and monitored using
sequential organ failures assessment (SOFA)-scores. On Days (D)
0, 1, 2 and 7 clinical data were recorded and blood was drawn for
determination of routine parameters and markers. Antibiotic
treatment and changes within the study period were recorded.
Routine chest- and sinus-radiographs were taken on D0 and 7,
all other diagnostic imaging were ordered by treating physicians,
blinded to results, as considered necessary. Blood samples for
microbiological culture were taken from indwelling arterial
catheters using delayed vial entry bottles for aerobic and anaerobic
cultures and processed according to protocol. Depending on
suspicion of local infection, specimens for microbial culture were
collected. Investigation of fungal, viral or atypical microorganisms
was left at the treating physician’s discretion. All culture and
staining results from specimens drawn between D0–7 were
evaluated. Positive cultures considered to represent colonization
were not considered to represent infection and microorganisms are
grouped according to genus. The presence of infection was
determined by researchers (SHH and ABJG) blinded to study
results and classified by likelihood into possible, probable or
proven infection, according to criteria defined at the International
Sepsis Forum Consensus Conference [35]. Infections are only
considered when probable or proven [3]. Sepsis was defined as
infection in the presence systemic inflammatory response syn-
drome (SIRS) criteria, according to ACCP/SCCM (American
Society of Chest Physicians/Society of Critical Care Medicine)
[36]. Criteria of shock criteria were a systolic arterial pressure
,90 mmHg or a mean arterial pressure (MAP) ,70 mmHg for at
least one hour, despite fluid resuscitation, or need of vasopressor
treatment. Shock in the presence of sepsis was marked septic
shock. Organ failure was assessed by the sequential organ failure
assessment (SOFA) score on Day 0, 1, 2 and 7.
Patients were divided into four categories of infectious course:
Group 1 with infection presenting at D0–2 and without evidence
of infection at D3–7, thus having a response to treatment and
resolving infection, Group 2 with infection presenting D0–2 and
persisting positive cultures from the same infection site and/or
persisting positive cultures with the same microorganism at D3–7,
thus having treatment failure, Group 3 without infection D0–2
and with infection D3–7, thus having a new infection, and Group
4 without infection D0–2 and D3–7. Complications of infection
were considered BSI, septic shock and outcome. Therefore a
similar division was done for BSI, irrespective of local cultures.
Group 1a with BSI presenting D0–2 and without BSI D3–7, thus
resolving BSI in response to treatment. Group 2a with BSI
presenting D0–2 and with persisting BSI D3–7, i.e. treatment
failure, Group 3a without BSI D0–2 and with infection D3–7,
having a new BSI and Group 4a without BSI D0–2 and D3–7.
Septic shock was defined by the presence of shock within 12 hours
prior or 12 hours after the determination of infection in either one
of the respective study intervals. Group 1b represents presence of
septic shock in D0–2 but without septic shock in D3–7, Group 2b
presents septic shock both in D0–2 and D3–7, Group 3b absence
of septic shock in D0–2 but presence of septic shock D3–7, and
Group 4b absence of septic shock in both study intervals.
Analogously, we divided patients with decreasing SOFA scores
(peak D0–2 to 7; Group 1c), unchanged SOFA scores (Group 2c)
and increasing SOFA scores (Group 3c). Outcome is 28-day
survival or all-cause mortality.
Routine parameters measured were white blood cell count
(WBC) (Sysmex SE-9000 analyzer, Toa Medical Instruments,
Kobe, Japan, normal values 4.5–10 x109/L), lactate (Enzymatic
method, Modular analytics ,P. Roche diagnostics, Mannheim,
Germany, normal values ,1.8 mmol/L) and C-reactive protein
(CRP, Immunoturbidimetric assay, Modular analytics ,P.
Roche diagnostics, Mannheim, Germany, normal values
,5 mg/L). Procalcitonin was measured through the Kryptor
compact system (Brahms Diagnostica, Henningsdorf, Germany,
normal values ,0.08 ng/L) using time resolved amplified cryptate
emission (TRACE) technology.
Statistical Analysis
CRP and PCT courses were expressed as fractional changes at
D7 vs. peak values at D0–2. To further separate differences in
absolute levels and changes, we used the Kruskal-Wallis test to
evaluate group differences in the respective values. Area under the
receiver operating characteristic curves (AUROC) were used to
evaluate predictive values, such as sensitivity and specificity of
optimal cut off values, defined at highest combined sensitivity and
specificity, and their statistical significance. Exact P values are
given unless ,0.001, and values ,0.05 were considered statisti-
cally significant. Data are expressed as number (percentage) or
median (range) in tables and median, interquartile range (IQR) in
Figure 1.
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Results
Table 1 represents patient characteristics and Table S1 infection
characteristics, grouped according to course of infection. Fifty-two
patients with new onset fever had resolving (Group 1) or no
(Group 4) infection and only twenty had non-resolving (Group 2)
or new (Group 3) infection, but (change of) treatment was mostly
successful and ultimate mortality did not differ among groups.
Most patients with infections had SIRS and therefore sepsis. The
number of days from ICU admission until study inclusion was
lowest in Group 2 and 3 and the need for vasopressor and renal
replacement therapy was highest in Group 3. Infections with yeast
were more persistent than infections with other microorganisms.
28-Day mortality in BSI was for Group 1a-4a 13, 100, 40 and
16%, respectively (P = 0.02), and in septic shock for Group 1b–4b
19, 40, 20 and 17%, respectively (P = 0.68).
Course of Infectious Disease, CRP and PCT
Figure 1 shows the differences in marker levels in time for the
infection groups. Table 2 shows that, among changes, those in
CRP, rather than PCT, differed between groups according to
infectious status, with a large decrease in Group 1 and persistently
high values in Group 2 and 3, whereas absolute values of both
CRP and PCT differed among groups. Table S2 shows that,
among changes, those in PCT best discriminated between BSI
groups, whereas absolute values of WBC, PCT and lactate at D7
differed among groups. Table S3 displays course in time for septic
shock showing that, among changes, those in PCT better
discriminated between groups than changes in CRP, whereas
absolute values of WBC (D7), CRP, PCT also differed among
groups. Table S4 shows that changes in SOFA score were
particularly associated with changes in PCT.
Predictive Values for Evolving Infectious Disease
Table 3 summarizes the predictive values of changes in markers
for resolving (Group 1, a, b or c) or new (Group 3, a, b, or c)
infection, BSI, septic shock or organ failure vs. other groups. Most
AUROC’s were above 0.70, with high specificities of optimal cut
off values. The table shows that CRP changes particularly predict
changes in the status of infections and their complications
knowingly BSI and septic shock, whereas PCT changes primarily
predict the latter complications and the course of organ failure.
Optimal cut off values are shown with decreases in markers by
86% or more and increases by 23% or more, and higher
sensitivities of PCT than of CRP.
D7 Values: Group Differences and Outcome Prediction
At D7, CRP had a cut off ,20.9 mg/L predicting Group 1 (at
AUROC 0.67, P = 0.01, sensitivity 31 and specificity 93%). For
PCT, the cut off was ,0.18 ng/mL (at AUROC 0.76, P,0.001,
sensitivity 63 and specificity 93%). For a PCT cut off ,0.5 ng/
mL sensitivity was 87 and specificity 45%. PCT at D7 also
predicted, at a cut off .7.8 ng/mL (AUROC 0.67, P = 0.03,
sensitivity 13 and specificity 96%), no decrease in SOFA score
(Group 3c+2c). On D7, only WBC and PCT were lower in 28-
day survivors than in non-survivors (P = 0.003 and 0.02,
respectively). The AUROC for non-survival for WBC at D7, at
an optimal cut off .33.1 x109/L, was 0.76 (P,0.001, with
sensitivity of 0 and specificity of 100%) and for PCT at D7 0.70
(P = 0.005, with sensitivity 29 and specificity 95%), at an optimal
cut off .2.6 ng/mL.
Discussion
This prospective, medium-sized study shows that changes in
CRP and PCT, rather than changes in WBC, in general critically
ill patients with new onset fever predict infectious courses in
response to treatment, but in a different manner. CRP changes
appear most predictive for changes in infectious status and
complications such as BSI and development of septic shock.
Whereas PCT changes primarily appear predictive for infectious
complications BSI, development of septic shock, associated organ
failure and death.
Figure 1. Evolution of C-reactive protein and procalcitonin according to evolution of infection (I) in febrile critically ill patients. CRP
and PCT levels presented as median (interquartile range). Group 1= I Day (D)0-2 no I D3-7; Group 2= I D0-2 and I D3-7; Group 3=no I D0-2 but I D3-7;
Group 4=no I D0-2 nor D3-7. For CRP D0-2 P = 0.009, for CRP D7 P= 0.002, for change P= 0.004; for PCT D0-2 P = 0.054, PCT D7 P,0.001, for change
P= 0.23, among groups.
doi:10.1371/journal.pone.0065564.g001
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Table 1. Patient characteristics.
Group 1 Group 2 Group 3 Group 4 P
n=30 n=9 n=11 n=22
General
Age (year) 62 (19–79) 63 (36–71) 68 (22–76) 66 (26–77) 0.91
Gender (male) 22 (73) 6 (68) 8 (73) 16 (73) 0.98
SAPS II on admission 48 (21–72) 49 (29–78) 50 (24–84) 45 (27–85) 0.99
Peak SOFA at D0–2 8 (3–13) 8 (3–13) 10 (4–14) 8 (3–16) 0.31
SOFA at D7 5 (0–15) 5 (4–14) 7 (5–13) 5 (2–21) 0.28
Temp uC D0–2 39.2 (38.5–40.8) 39.3 (38.6–40.0) 39.0 (38.7–40.0) 39,0 (35,8–39,8) 0.80
D7 37.6 (36.5–39.0) 39,2 (36,7–40,0) 38,1 (37,3–39,7) 37,8 (36,5–40,0) 0.03
Change 0,96 (0,89–1,00) 1,00 (0,93–1,02) 0,98 (0,94–1,03) 0,96 (0,93–1,00) 0.05
SIRS, D0–2 30 (100) 9 (100) 11 (100) 22 (100) 1.0
D7 23 (85) 9 (100) 9 (82) 17 (90) 0.65
Sepsis, D0–2 30 (100) 9 (100) 0 (0) 0 (0) 1.00
D7 0 (0) 9 (100) 9 (82) 0 (0) 0.19
Septic shock, D0–2 15 (50) 6 (67) 0 (0) 0 (0) 0.39
D7 0 (0) 7 (78) 8 (73) 0 (0) 0.80
Days from admission to D0 7 (1–77) 4 (1–12) 5 (1–16) 12 (2–78) 0.01
Duration mechanical ventilation, days
22 (5–82) 26 (4–42) 16 (11–82) 35 (10–123) 0.15
ICU length of stay, days 28 (10–95) 26 (12–44) 26 (12–85) 37 (11–126) 0.41
28-day mortality 5 (17) 2 (22) 2 (18) 5 (23) 0.95
ICU mortality 7 (23) 1 (11) 2 (18) 5 (23) 0.87
Admission category
Trauma 4 (13) 1 (11) 2 (18) 4 (18) 0.94
Surgery
general 17 (57) 6 (67) 9 (82) 13 (59) 0.50
cardiac 1 (3) 1 (11) 1 (9) 3 (14) 0.60
vascular 2 (7) 1 (11) 4 (36) 9 (2) 0.08
Neurologic 5 (17) 2 (22) 1 (9) 3 (14) 0.86
Respiratory insufficiency 17 (57) 2 (22) 4 (36) 7 (32) 0.16
post CPR 3 (10) 0 (0) 2 (18) 0 (0) 0.18
Sepsis 12 (40) 3 (33) 1 (9) 7 (32) 0.32
Shock 9 (30) 1 (11) 0 (0) 7 (32) 0.13
Treatment up to 7 days prior to inclusion
Corticosteroids 14 (47) 3 (33) 4 (36) 12 (55) 0.65
SDD 8 (27) 2 (22) 4 (36) 12 (55) 0.65
Surgery 4 (13) 2 (22) 1 (9) 2 (9) 0.77
Treatment during study D0–7
Antibiotics 30 (100) 9 (100) 11 (100) 19 (86) 0.07
Change in antibiotics 20 (67) 8 (89) 7 (64) 13 (59) 0.46
Corticosteroids 19 (63) 4 (44) 4 (36) 12 (55) 0.65
SDD 8 (27) 2 (22) 4 (36) 12 (55) 0.65
Mechanical ventilation 29 (97) 8 (89) 11 (100) 22 (100) 0.35
Inotropic/vasopressors 16 (57) 8 (89) 11 (100) 13 (59) 0.03
Renal replacement therapy 1 (3) 0 (0) 4 (36) 2 (9) 0.01
Surgery 3 (10) 1 (11) 2 (18) 3 (14) 0.91
Median (range), or number (percentage); SAPS = simplified acute physiology score; SOFA = sequential organ failure assessment score; ICU = intensive care unit;
CPR = cardiopulmonary resuscitation; SDD= selective decontamination of the digestive tract. Group 1= infection (I) Day (D)0–2 not D3–7; Group 2= I D02 and I D3–7;
Group 3= no I D0–2 but D3–7; Group 4= no I D0–2 nor D3–7.
doi:10.1371/journal.pone.0065564.t001
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Our study is the third one comparing CRP and PCT and the
second one comparing their courses in the evolution of
nosocomial infection in the general critically ill patient with
new onset fever [9,12]. Our data do not suggest different
kinetics per se over a 5–7 day course, in contrast to the slower
kinetics of CRP than of PCT in the critically ill suggested by
others [4,6,8,10,12,15,27,31,34]. This study however, suggests
that CRP changes are more associated with evolution of
infection and PCT more with evolution of adverse infectious
sequelae. Although the AUROC’s of changes in markers seem
higher than those for absolute levels, our current findings on
absolute levels are in line with those reported earlier [3],
Table 2. Evolution of infection.
Group 1 Group 2 Group 3 Group 4 p
n=30 n =9 n =11 n =22
WBC D0–2, x109/L 13.9 (2.5–24.4) 12.8 (7.9–81.7) 16.2 (9.0–24.8) 11.6 (7.8–23.9) 0.22
WBC D7, x109/L 11.5 (4.9–23.2) 16.9 (8.3–30.2) 16.2(6.4–33.0) 11.9 (5.3–29.2) 0.06
WBC change 0.80 (0.47–3.20) 0.75 (0.37–1.41) 1.16 (0.40–2.95) 0.94 (0.50–1.65) 0.55
CRP D0–2, mg/L 210 (5–397) 303 (102–421) 145 (38–440) 137 (27–248) 0.009
CRP D7, mg/L 57 (2–267) 182 (22–416) 156 (49–304) 62 (6–265) 0.002
CRP change 0.40 (0.02–1.15) 0.68 (0.07–1.82) 0.93 (0.44–6.97) 0.58 (0.11–2.58) 0.004
PCT D0–2, ng/mL 0.5 (0.08–45.1) 2.6 (0.08–75.3) 1.7(0.3–6.3) 0.8 (0.1–2.8) 0.054
PCT D7, ng/mL 0.1 (0.06–38.5) 0.6 (0.1–24.3) 1.3 (0.3–20.8) 0.2 (0.08–4.3) ,0.001
PCT change 0.30 (0.05–1.57) 0.42 (0.04–2.97) 0.52 (0.08–68.3) 0.44 (0.11–5.88) 0.23
Lactate D0–2, mmol/L 1.6 (0.5–3.5) 1.5 (0.9–3.5) 1.3 (1.0–2.3) 1.4 (0.5–2.0) 0.60
Lactate D7 mmol/L 1.1 (0–4.3) 1.1 (0.9–3.1) 1.1 (0.7–1.8) 1.0 (0.5–2.2) 0.67
Lactate change 0.77 (0–2.08) 0.95 (0.48–1.72) 0.85 (0.43–1.60) 1.06 (0.42–1.50) 0.32
Median (range) for WBC=white blood cell count; CRP= C-reactive protein; PCT = procalcitonin; Group 1= infection.
(I) Day (D)0–2 not D3–7; Group 2= I D0–2 and I D3–7; Group 3= no I D0–2 but D3–7; Group 4= no I D0–2 nor D3–7.
doi:10.1371/journal.pone.0065564.t002
Table 3. Predictive values for changes of markers.
Infection Resolving (Group 1) New (Group 3)
Cut off AUROC P Sens Spec PPV NPV Cut off AUROC P Sens Spec PPV NPV
WBC change – – – – – – – – – – – – – –
CRP change ,0.14 0.72 ,0.001 31 93 75 65 .2.57 0.76 ,0.001 20 100 100 88
PCT change – – – – – – – – – – – – – –
Bloodstream infection
Resolving (Group 1a) New (Group 3a)
Cut off AUROC P Sens Spec PPV NPV Cut off AUROC P Sens Spec PPV NPV
WBC change – – – – – – – .2.57 0.87 ,0.001 20 98 50 94
CRP change ,0.04 0.73 0.04 29 57 50 92 .2.95 0.84 ,0.001 20 100 100 94
PCT change – – – – – – – .2.00 0.89 ,0.001 60 97 60 97
Septic shock Resolving (Group 1b) New (Group 3b)
Cut off AUROC P Sens Spec PPV NPV Cut off AUROC P Sens Spec PPV NPV
WBC change – – – – – – – – – – – – – –
CRP change ,0.06 0.70 0.01 31 98 83 83 .2.57 0.83 ,0.001 20 100 100 81
PCT change ,0.13 0.72 0.007 31 93 56 83 .1.78 0.82 ,0.001 50 97 71 92
SOFA scores Not increasing (Group 1c+2c) Not decreasing (Group 2c+3c)
Cut off AUROC P Sens Spec PPV NPV Cut off AUROC P Sens Spec PPV NPV
WBC change – – – – – – – – – – – – – –
CRP change – – – – – – – .2.95 0.67 0.02 6 100 100 78
PCT change – – – – – – – .1.23 0.73 0.001 38 92 60 83
WBC=white blood cell count; CRP= C-reactive protein; PCT = procalcitonin; AUROC= area under the receiver operating characteristic curve; Sens = sensitivity;
Spec = specificity at optimal cut off values. PPV = positive predictive value; NPV= negative predictive value. Statistically significant AUROC’s are given only. A value less
than 1 denotes a fractional decrease from Day 0–2 to 7 and a value above 1 a fractional increase.
doi:10.1371/journal.pone.0065564.t003
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suggesting that during nosocomial fever in the critically ill CRP
is more likely to contribute to infection diagnosis whereas PCT
has better capability of predicting risks of infections. PCT has
also been reported to be capable, more than CRP, of early
discrimination between [severe] infection or sepsis on the one
hand and non-infectious SIRS or uncomplicated infection on
the other [2,4–6,8–10,12]. PCT increases predicted blood-
stream invasion, septic shock and organ failure and carried
greater prognostic significance in the course of infectious disease
than CRP [on D7] thus supporting that PCT is more useful in
predicting infectious complications, also in the ICU, even when
not predicting new BSI [2,4–6,8–10,12,14,20,24–27,30,31]. In
leptospirosis, PCT normalises upon treatment in 4 days and
CRP within 7 days in non-severe cases and both return to
normal in 7 days in severe infections [19], suggesting greater
sensitivity of PCT than of CRP to infection severity, in line with
our data. Conversely, we can assume in line with others
[10,15,17,21–23,28,29,31,32], that the decrease in CRP in
Group 1 with resolving infection resulted from appropriate
antibiotic treatment, so that we cannot exclude that the
persistent infection in Group 2 with less decreases was caused
by treatment failure or slow response, even though not
associated with increased mortality. The threshold for CRP at
D7 to decide on the resolution of infection only is about 21 mg/
L. Our study does not agree with the relation between rate of
decline in CRP up to D7 during treatment for infection in the
ICU and survival [22,24,26–29,31], since the change of CRP
did not predict outcome. The difference with our study may
relate to differences in inclusion criteria, among others. Our
study suggesting greater value of decreases in CRP than of PCT
in resolving nosocomial infection in the ICU, does also not
agree with the reported superior value of PCT decreases in
predicting response of infections to treatment [10,15,26,31]. A
decrease of PCT to 0.5–1.0 ng/mL or lower has otherwise been
used for allegedly safe discontinuation of antibiotics in patients
with presumed infection given antibiotics with high likelihood
for survival in the ICU [8–10,12,16,24,26,27,31,33]. However,
our data are not in line with this threshold and suggest a lower
value of about 0.2 ng/mL, after one week treatment, since the
values associated with non-resolving infection, increasing SOFA
and mortality are higher.
Some limitations of this study should be addressed. A fair
number of patients received corticosteroids, including so called low
dose steroids for treatment of relative adrenal insufficiency during
sepsis, prior and during inclusion, but this may hardly affect
marker levels as related to the course of infection as our data in
line with those of others suggest [13,17,37]. We used selective
decontamination of the digestive tract by non-absorbable antibi-
otics for infection prevention in many of our patients but the use
apparently did not confound the value of CRP and PCT
[changes]. We cannot exclude that Group 4 patients without
infections had benefited from this type of infection prevention and
had received overtreatment by empiric antibiotics, in the absence
of demonstrable microbial infection. We chose to classify all
groups similar to our primary outcome variable: course of
infectious disease, thus always entailing four groups per outcome
measure, except for SOFA score. This resulted in uneven numbers
per patient group, and the small number of patients in group 2a is
a consequence of this uniform categorisation. However, small
groups may not invalidate statistical significance. The study carries
the advantage over many others [2,4–7,17,30–32] of documenta-
tion of microbial infection and definitions of infectious complica-
tions [rather than stages of ‘sepsis’] in the critically ill. Finally, our
study lacks daily measurements, as other have done in spite of
increasing costs [2,5–11,14,15,18,20,21–23,25,31,32], so that we
cannot conclude on rapid time courses of the infection markers.
However, our data suggest clinical usefulness of the sampling
regimen followed. We did not evaluate biomarker changes over
shorter periods since the kinetics of resolving and developing
infections may differ according to infectious focus and causative
microorganism, among others.
In conclusion, our study on ICU-acquired fever and infections
suggests that CRP may be favoured over PCT courses over 5–7
days in judging response to antibiotic treatment, whereas the latter
may better indicate the risk of complications, such as bloodstream
infection, septic shock, organ failure and mortality, which may
help deciding on safe discontinuation of antibiotics. The analysis
may thus help interpreting current literature and design future
studies on guiding antibiotic therapy in the ICU.
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